At the research peptide level, retatrutide and tirzepatide cost roughly the same ($150$500/month depending on dose)
Everyone is different, so dosing can be adjusted until you get the desired results
From a regulatory and liability perspective, this is the only position a pharmaceutical manufacturer can reasonably take
Vague Labeling: Avoid products that do not clearly specify the exact peptide content, molecular weight, or Research Only status
Additional GLP-1 agonists include exenatide (brand name Byetta), lixisenatide (Adlyxin), and dulaglutide (Trulicity)
At most, we should treat them like harmful foods, which Maimonides does not explicitly prohibit, although he writes that people should avoid eating them ( Deot 4:9).[2] Unlike weight loss medicines, these foods have no medical benefit, only potential negative effects on health